Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Alger Health Sciences C AHSCX
- NAV / 1-Day Return 13.49 / +0.67 %
- Total Assets 105.8 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.950%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 306%
USD | NAV as of Jul 27, 2024 | 1-Day Return as of Jul 27, 2024, 1:20 AM GMT+0
Morningstar’s Analysis AHSCX
Will AHSCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 5.34 | 5.8 Mil | Healthcare |
Boston Scientific Corp | 5.25 | 5.7 Mil | Healthcare |
McKesson Corp | 5.19 | 5.6 Mil | Healthcare |
Novo Nordisk A/S ADR | 5.10 | 5.5 Mil | Healthcare |
Elevance Health Inc | 4.88 | 5.3 Mil | Healthcare |
Amgen Inc | 4.10 | 4.5 Mil | Healthcare |
AstraZeneca PLC ADR | 4.02 | 4.4 Mil | Healthcare |
Merck & Co Inc | 3.92 | 4.3 Mil | Healthcare |
Intuitive Surgical Inc | 3.42 | 3.7 Mil | Healthcare |
Oscar Health Inc Class A | 3.30 | 3.6 Mil | Healthcare |